WO2002024212A1 - Cholesterol in blood-lowering composition and its complex, and method for preparing them - Google Patents
Cholesterol in blood-lowering composition and its complex, and method for preparing them Download PDFInfo
- Publication number
- WO2002024212A1 WO2002024212A1 PCT/KR2000/001034 KR0001034W WO0224212A1 WO 2002024212 A1 WO2002024212 A1 WO 2002024212A1 KR 0001034 W KR0001034 W KR 0001034W WO 0224212 A1 WO0224212 A1 WO 0224212A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholesterol
- blood
- reducing
- phyto
- sterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
Definitions
- the present invention relates to the composition and the complex for reducing the cholesterol in the blood, particularly LDL cholesterol, and for curing the cholesteremia or some of heart diseases, as well as to the method for manufacturing those compositions and complex substances, wherein complexes or mixed compositions consisting of phyto-sterols, naturally occurring plant sterols and tannins, as the main components, are used as pharmaceutical preparations, medicinal injections, food additives or the like.
- the cholesterol is an essential substance in human body, which plays a role in forming cell membrane, steroid hormones or the like.
- the in-blood concentration of cholesterol, particularly LDL cholesterol or the lipid is maintained at excessively high level, however, there is a high possibility of heart diseases or arterial sclerosis, which can lead to death or disability.
- the plant sterols are effective in controlling the choiesterols in the blood substantially without causing harmful effects (Reference: J. Nutr., 107, 2011 (1977)).
- the beta-cytosterol which is advantageously acquired from bean or rice in easy ways and which turns similar to the cholesterol in structure when the ethyl group at the 24-th carbon is removed, has been confirmed to interfere with the cholesterol absorption in the human body through a competitive reaction (Reference: Atherosclerosis, 28, 325, (1977)).
- Naturally occurring plant sterols have the same skeleton in the structure, only slightly differing in side chains.
- the plant sterols taken-in together with foodstuffs are mostly either beta-cytosterols or campysterols, some of which are absorbed in the intestine and then discharged outside the body, so that even an over- intake causes no side effect on the human body due to only a minor part of it remaining in the body.
- their analogous products i.e. stanol as hydrogenated compounds and their fatty acid ester compounds were also developed as the products for reducing in-blood choiesterols (Reference: J. Lipid Res., 20, 646, (1979); J.
- the complex for reducing the in-blood cholesterol according to the present invention comprises, as the principal components, natural plant sterol ("phyto-sterol”) and tannin at the weight ratio of 10: 1 to 1:10.
- phyto-sterol natural plant sterol
- tannin tannin
- the present inventors have confirmed that the phyto-sterol/tannin complexes manufactured by mixing naturally occurring plant sterols as harmless safe substances, and tannins have an unexpected synergic effect in reducing the in-blood choiesterols and so completed the present invention based on that finding.
- phytosterols beta-cytosterols, campy-sterols, stigma sterols, fuco-sterols, Brassica sterols may be mentioned.
- One of those sterols or a mixture of two or more may be used as the principal component for the products according to the invention.
- the tannins as described above are generally included in the stems, leaves, roots of plants or the like, and also in the fruits and vegetables including unripe ones, as well as in the seeds of plants.
- the tannin compounds have various physiological activities, which include, for example, the action of improving the blood circulation, anti-oxidation and other various physiological activations.
- the tannins may be classified as (1) catechins and their derivatives, (2) leucoanthocyanins,
- chlorogenic acids which all belong to polyphenolic acids with phenol group(s).
- the tannin compounds as described above can be used as a single compound or in the form of mixture of two or more compounds.
- catechins which have the carbon skeletons of C 6 -C 3 -C 6 , i.e. a structural characteristic common to the flavonoids, anthocyanins and the like. Under these tannins, catechins
- Typical leucoanthocyanins may include leucoanthocyanidin, luteolinidin and the like.
- the anthocyanidins have the basic structure of 3,5,7-trihydroxy flavylium chlorides.
- the anthocyanidin includes pelargonidin, cyaniding and delphinidin as the representative examples and further includes hirsutidin (7-o-methylmalvidin), aurantinidin (8-hydroxy pelargonidin), apigeninidin (3-deoxy pelargonidin), petunidin
- the representative examples of the above-described polyphenolic acids include chlorogenic acids, caffeine acid, phenyl caffeate, cinnamic acid, gallic acid and the tannic acid that is now known as a complex mixture of various compounds.
- the tannins have a variety of distributions and contents and they can be relatively easily extracted to give certain desired tannin.
- the content ratio between phyto-sterol and tannin as the principal components of the complex according to the invention lies between 10:1 and 1:10 and more preferably between 4:6 and 6:4, each ratio being by weight, as mentioned earlier.
- the present invention relates to a mixed composition comprising, as the principal components, phyto-sterol and tannin at the weight ratio of 10: 1 to 1 : 10 for reducing the cholesterol in the blood.
- the complex of phyto-sterol and tannin which is obtained by dissolving the phyto-sterol and tannin together in a solvent and then heat-treating the dissolved mixture at a defined condition further increases the synergic effect of mixing the two ingredients.
- the present invention relates to a method for manufacturing a complex of phyto-sterol/tannin as well.
- the method for manufacturing the complex for reducing the in-blood cholesterol according to the present invention comprises dissolving the dried phyto- sterol and tannin in a solvent under an acidic condition, subjecting the dissolved mixture to reaction at a temperature from 20 to 100°C, removing the remaining solvent from the product and finally subjecting the crude product to drying.
- the manufacturing method comprises the steps of:
- the temperature in the above steps (C) and (D) is about 70°C and the heating period is 5 to 30 minutes.
- the solvent used in the step (B) the water, ethanol or a mixture of water and ethanol may be appropriate.
- the weak solution for the step (D) preferably an edible acidic solution and most preferably vinegar from fruit may be used.
- the complex and mixed composition according to the invention may be prepared into pharmaceutical formulations, medicinal injections, food additives or the like for reducing the cholesterol level in the blood.
- a pharmaceutical formulation may be prepared by adding some vehicle to the above-described complex as the active ingredient.
- a medicinal injection may be prepared by dissolving the above complex as the active ingredient in distilled water or saline solution as the solvent.
- powder of the complex is simply added to the raw material of foodstuffs and finished foodstuffs.
- the present invention relates to the agents for reducing cholesterol, injections for reducing cholesterol, food additives for reducing cholesterol, each containing the above-described complexes or mixed compositions as the active ingredients, and various foodstuffs containing the above complexes.
- the method for preparing the above agents, injections and foodstuffs is the same as the method for preparing ordinary medicinal agents or injections based on the medicinal active components, and therefore is no more described.
- addition can be made in a variety of ways only under the condition of not damaging the present main components. In other words, when an excessive heat is applied in the course of manufacturing a foodstuff, the addition is conducted at the unheated final stage, while an excessive heat is not applied in the course of manufacturing foodstuff, the complex material is added together with the raw material before processing.
- the foodstuffs are not restricted, as far as the form is concerned. For instance, the foodstuffs in liquid form such as beverage or the foodstuffs in solid form such as meat for hamburger can be covered.
- the present invention relates to a method for reducing the in- blood cholesterol content and suppressing the cholesterol absorption by using the complex or mixed composition of interest in medicinal agents, medicinal injections, foodstuff additives or the like.
- a method for reducing the in- blood cholesterol content and suppressing the cholesterol absorption by using the complex or mixed composition of interest in medicinal agents, medicinal injections, foodstuff additives or the like includes the cure of high cholesterol symptoms and some of heart diseases.
- beta-cytosterol 200 mg of beta-cytosterol, a kind of phyto sterol, and 280 mg of catechin, a kind of tannin, were well mixed and dried at normal temperature for 30 minutes.
- aqueous ethanol solution 50 mg
- catechin a kind of tannin
- the solution was heated at 70°C for about 20 minutes.
- the resulting substance was cooled to the normal temperature over 30 minutes and then acidified by adding 10 ml of fruit vinegar.
- the acidified solution was further agitated at the normal temperature for 15 minutes and then heated at 70°C for about 5 minutes.
- the excessive solvent was removed, and the formed product was dried and filtered through a 20 mesh-sieve to produce a uniform product.
- the complex substance of the present invention reduces the total cholesterol number in the blood as well as the LDL- cholesterol without influencing the absorption of favorable HDL-cholesterol to attain a satisfactory result.
- the complexes according to the invention are effective in curing high cholesterol symptoms and in preventing heart diseases and hypertension, they can be used not only in medicinal preparations or injections but also can be used in manufacturing health-oriented functional foodstuffs by simply incorporating in other foodstuffs and beverages.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2000/001034 WO2002024212A1 (en) | 2000-09-25 | 2000-09-25 | Cholesterol in blood-lowering composition and its complex, and method for preparing them |
| AU2000274550A AU2000274550A1 (en) | 2000-09-25 | 2000-09-25 | Cholesterol in blood-lowering composition and its complex, and method for preparing them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2000/001034 WO2002024212A1 (en) | 2000-09-25 | 2000-09-25 | Cholesterol in blood-lowering composition and its complex, and method for preparing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002024212A1 true WO2002024212A1 (en) | 2002-03-28 |
Family
ID=19198267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2000/001034 Ceased WO2002024212A1 (en) | 2000-09-25 | 2000-09-25 | Cholesterol in blood-lowering composition and its complex, and method for preparing them |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2000274550A1 (en) |
| WO (1) | WO2002024212A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1264596A3 (en) * | 2001-06-05 | 2003-01-08 | Kao Corporation | Use of a ferulic acid derivative as a preventive or remedy for hypertension |
| WO2007063158A2 (en) | 2005-11-30 | 2007-06-07 | La Morella Nuts, S.A. | Functional food having positive effects in the prevention of cardiovascular diseases |
| US7772195B2 (en) * | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| US7811781B2 (en) | 2005-07-06 | 2010-10-12 | Btg International Limited | Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis |
| US7906493B2 (en) | 2003-12-22 | 2011-03-15 | Btg International Limited | Core 2 GlcNAc-T inhibitors |
| US7998943B2 (en) | 2005-07-06 | 2011-08-16 | Btg International Limited | Core 2 GlcNAc-T inhibitors III |
| US8197794B2 (en) | 2003-12-22 | 2012-06-12 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
| US8609633B2 (en) | 2005-07-06 | 2013-12-17 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000019718A (en) * | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising tannin or phenol-type compounds derived from tannin for preventing and treating hyperlipidemia, arteriosclerosis and liver disease |
-
2000
- 2000-09-25 WO PCT/KR2000/001034 patent/WO2002024212A1/en not_active Ceased
- 2000-09-25 AU AU2000274550A patent/AU2000274550A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000019718A (en) * | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising tannin or phenol-type compounds derived from tannin for preventing and treating hyperlipidemia, arteriosclerosis and liver disease |
Non-Patent Citations (4)
| Title |
|---|
| AGRIC. BIOL. CHEM., vol. 54, no. 1, 1990, pages 171 - 175 * |
| AM. J. MED., vol. 107, no. 6, 1999, pages 588 - 594 * |
| LIPIDS, vol. 27, no. 3, 1992, pages 181 - 186 * |
| PHARMACOL. RES., vol. 35, no. 6, 1997, pages 505 - 512 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1264596A3 (en) * | 2001-06-05 | 2003-01-08 | Kao Corporation | Use of a ferulic acid derivative as a preventive or remedy for hypertension |
| US6894077B2 (en) | 2001-06-05 | 2005-05-17 | Kao Corporation | Preventive or remedy for hypertension |
| US7534815B2 (en) | 2001-06-05 | 2009-05-19 | Kao Corporation | Preventive or remedy for hypertension |
| US7939563B2 (en) | 2001-06-05 | 2011-05-10 | Kao Corporation | Remedy for hypertension |
| US7906493B2 (en) | 2003-12-22 | 2011-03-15 | Btg International Limited | Core 2 GlcNAc-T inhibitors |
| US8197794B2 (en) | 2003-12-22 | 2012-06-12 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
| US7772195B2 (en) * | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| US8198249B2 (en) * | 2004-07-29 | 2012-06-12 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| US7811781B2 (en) | 2005-07-06 | 2010-10-12 | Btg International Limited | Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis |
| US7998943B2 (en) | 2005-07-06 | 2011-08-16 | Btg International Limited | Core 2 GlcNAc-T inhibitors III |
| US8609633B2 (en) | 2005-07-06 | 2013-12-17 | Ms Therapeutics Limited | Core 2 GlcNAc-T inhibitors |
| WO2007063158A2 (en) | 2005-11-30 | 2007-06-07 | La Morella Nuts, S.A. | Functional food having positive effects in the prevention of cardiovascular diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2000274550A1 (en) | 2002-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Igile et al. | Nutritional assessment of Vernonia amygdalina leaves in growing mice | |
| EP0282002A2 (en) | Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care | |
| JP2007535576A (en) | Nutritional composition that promotes rapid weight loss, burns calories, increases heat generation, assists in energy metabolism and / or suppresses appetite | |
| US20150201661A1 (en) | Bamboo extracts, compositions and uses thereof | |
| AU2007245223C1 (en) | Fat absorption inhibitor | |
| Elhassaneen et al. | Effect of some plant parts powder on obesity complications of obese rats | |
| WO2011112118A1 (en) | Premix for food for farm animals | |
| CN106173194A (en) | A kind of biological antioxidant of animal feed | |
| WO2002024212A1 (en) | Cholesterol in blood-lowering composition and its complex, and method for preparing them | |
| KR20100109697A (en) | Functional composition with the effects of improving hyperlipidemia and reducing body weight | |
| RU2115336C1 (en) | Bioactive preparation "propolin" | |
| JPH1175770A (en) | Lipid peroxide production inhibitor, its production method and use | |
| CN109645232A (en) | A kind of Chinese herbal medicine composite feed additive for treating animal diarrhea | |
| KR101045279B1 (en) | Composition of functional food having anti-obesity effect | |
| CN120114523A (en) | A lipase inhibitor with specific structure and its preparation method and application | |
| KR101793098B1 (en) | Natural plant mixed extracts that regulate heat of the skin and a cosmetic composition for skin heat anti-aging that containing the same | |
| RU2375434C2 (en) | Composition of balsam components | |
| KR100466946B1 (en) | Feed for Duck and Method of Feeding Duck with the Feed | |
| JP6778506B2 (en) | Functional food composition | |
| CN106173195A (en) | A kind of animal feed preparation method of biological antioxidant | |
| JPH07112979B2 (en) | Active oxygen free radical scavenger | |
| JP2009221158A (en) | Neutral fat reducing agent and body fat increase inhibitor | |
| El-Maaty et al. | Performance of hybrid chickens as influenced by phytogenic extracted meal-supplemented diet as antibiotic alternatives during summer | |
| RU2392825C1 (en) | Feed supplement for farm livestock | |
| JP2009196967A (en) | Agent for increasing relative quantity of polyunsaturated fatty acid in blood, and pharmaceutical composition, quasi-drug, cosmetics, edible composition and animal feed containing the agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1020037004223 Country of ref document: KR |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING THE LOSS OF RIGHTS PURSUANT TO RULE 69 (1)EPC (EPO COMMUNICATION FORM 1205A DATED 30.07.2003) |
|
| 122 | Ep: pct application non-entry in european phase | ||
| WWR | Wipo information: refused in national office |
Ref document number: 1020037004223 Country of ref document: KR |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1020037004223 Country of ref document: KR |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |